Vesicare
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $562.64 | 31 | 31 |
| 2023 | $47.39 | 2 | 2 |
| 2022 | $244.73 | 4 | 4 |
| 2017 | $21,531 | 872 | 420 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $12,537 | 905 | 56.0% |
| Unspecified | $6,359 | 2 | 28.4% |
| Consulting Fee | $3,200 | 1 | 14.3% |
| Travel and Lodging | $290.00 | 1 | 1.3% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, Open-Label, Baseline-controlled, Multicenter, Sequential Dose Titration Study to Assess the Long-Term Efficacy and Safety, and the Pharmacokinetics of Solifenacin Succinate Suspension in Patients From 5 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) | Astellas Pharma Global Development | $5,749 | 1 |
| A Phase 3, Open-Label, Baseline-controlled, Multi-center, Sequential Dose-Titration Study to Assess the Pharmacokinetics, Long-Term Efficacy and Safety of Solifenacin Succinate Suspension in Children From 6 Months to Less Than 5 Years of Age With Neurogenic Detrusor Overactivity | Astellas Pharma Global Development | $609.85 | 1 |
Top Doctors Receiving Payments for Vesicare
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Urology | New Haven, CT | $9,849 | 4 |
| , M.D | Urology | Bowling Green, KY | $149.65 | 10 |
| , MD | Urology | Evansville, IN | $142.87 | 11 |
| , M.D | Student in an Organized Health Care Education/Training Program | Paducah, KY | $136.03 | 13 |
| , MD | Urology | Evansville, IN | $134.63 | 10 |
| , M.D | Urology | Bowling Green, KY | $120.34 | 8 |
| , M.D | Urology | Paducah, KY | $119.67 | 12 |
| , M.D | Surgery | Paducah, KY | $108.76 | 9 |
| , MD | Family Medicine | Cynthiana, KY | $108.72 | 6 |
| , MD | Family Medicine | Cynthiana, KY | $108.72 | 6 |
| , MD | Family Medicine | Cynthiana, KY | $108.72 | 6 |
| , M. D | Urology | Cape Girardeau, MO | $102.22 | 8 |
| , MD | Urology | Evansville, IN | $101.27 | 8 |
| , M.D | Family Medicine | Lexington, KY | $96.48 | 9 |
| , MD | Urology | Evansville, IN | $96.16 | 8 |
| , M.D | Internal Medicine | Statesville, NC | $95.93 | 9 |
| , D. O | Urology | Cape Girardeau, MO | $88.77 | 7 |
| Danilo Corales | Internal Medicine | Lexington, KY | $86.86 | 8 |
| , M.D | Internal Medicine | Statesville, NC | $85.98 | 9 |
| , M.D | Internal Medicine | Statesville, NC | $85.33 | 8 |
| , MD | Urology | Hopkinsville, KY | $82.11 | 6 |
| , MD | Urology | Chicago, IL | $82.05 | 4 |
| , MD | Internal Medicine | Statesville, NC | $80.55 | 7 |
| , M.D | Internal Medicine | Statesville, NC | $80.55 | 7 |
| Mahendra Narendran | Infectious Disease | Statesville, NC | $80.55 | 7 |
Manufacturing Companies
- Astellas Pharma US Inc $12,537
- Astellas Pharma Global Development $6,359
- Astellas Pharma Europe BV $3,490
Product Information
- Type Drug
- Total Payments $22,386
- Total Doctors 457
- Transactions 909
About Vesicare
Vesicare is a drug associated with $22,386 in payments to 457 healthcare providers, recorded across 909 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma US Inc.
Payment data is available from 2017 to 2024. In 2024, $562.64 was paid across 31 transactions to 31 doctors.
The most common payment nature for Vesicare is "Food and Beverage" ($12,537, 56.0% of total).
Vesicare is associated with 2 research studies, including "A Phase 3, Open-Label, Baseline-controlled, Multicenter, Sequential Dose Titration Study to Assess the Long-Term Efficacy and Safety, and the Pharmacokinetics of Solifenacin Succinate Suspension in Patients From 5 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (NDO)" ($5,749).